Hoerauf, Hans

[["dc.bibliographiccitation.firstpage","232"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","237"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Springer-Wanner, Christina"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Jungmann, Stephanie"],["dc.contributor.author","Brauns, Thomas"],["dc.contributor.author","Fulle, Gergana"],["dc.contributor.author","Eichel, Sebastian"],["dc.contributor.author","Koss, Michael Janusz"],["dc.contributor.author","Kuhli-Hattenbach, Claudia"],["dc.date.accessioned","2018-11-07T10:28:35Z"],["dc.date.available","2018-11-07T10:28:35Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose: To evaluate the efficacy of intravitreal dexamethasone implant for the treatment of postoperative persistent cystoid macular edema (CME) following macular pucker surgery. Methods: In this multicenter study, we retrospectively reviewed the data of 37 patients (39 eyes) who had been treated with intravitreal dexamethasone implant (Ozurdex (R)) for persistent CME following macular pucker surgery. Main outcome measures were change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Results: All eyes underwent spectral domain optical coherence tomography examination within 130 days after implantation. We observed a significant decrease in mean CRT from 519.9 to 392.9 mu m (p < 0.0001). By this time, mean BCVA had improved from 0.60 to 0.43 logMAR (p = 0.003). Seventeen eyes (43.6%) required at least 1 repeat injection of dexamethasone. Of these, 8 (47%) eyes received a total number of 3 or more dexamethasone injections. Conclusion: Intravitreal dexamethasone implant injection is an effective treatment option for persistent CME following macular pucker surgery. (C) 2017 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000464259"],["dc.identifier.isi","000402745800003"],["dc.identifier.pmid","28463851"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43454"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Karger"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.title","Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2021-06-01T10:49:09Z"],["dc.date.available","2021-06-01T10:49:09Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00347-021-01364-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86186"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","The urgency of surgical treatment for rhegmatogenous retinal detachment"],["dc.title.translated","Dringlichkeit der operativen Versorgung bei der rissbedingten Netzhautablösung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","604"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Current Eye Research"],["dc.bibliographiccitation.lastpage","614"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Vögeler, Jessica"],["dc.contributor.author","Priglinger, Siegfried"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Rehak, Matus"],["dc.date.accessioned","2021-04-14T08:26:42Z"],["dc.date.available","2021-04-14T08:26:42Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/02713683.2019.1679839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82046"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1460-2202"],["dc.relation.issn","0271-3683"],["dc.title","Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e933"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e941"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Rose, Uwe"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/aos.13770"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76197"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.volume","232"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Pankaj, Puri"],["dc.contributor.author","Berk, Huesnue"],["dc.contributor.author","Knorr, Thomas"],["dc.date.accessioned","2018-11-07T09:45:40Z"],["dc.date.available","2018-11-07T09:45:40Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000345450600236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34673"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.title","Efficacy and Safety of 0.5 mg Ranibizumab Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Central Retinal Vein Occlusion Over 6 Months: The COMRADE-C Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.volume","232"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Lang, Gabrielle"],["dc.contributor.author","Taylor, Simon"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Knorr, Thomas"],["dc.date.accessioned","2018-11-07T09:45:39Z"],["dc.date.available","2018-11-07T09:45:39Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000345450600235"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34672"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.title","Efficacy and Safety of 0.5 mg Ranibizumab Administered as Intravitreal Injections PRN Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Branch Retinal Vein Occlusion Over 6 Months: The COMRADE-B Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","858"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.bibliographiccitation.lastpage","865"],["dc.bibliographiccitation.volume","117"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2021-04-14T08:24:48Z"],["dc.date.available","2021-04-14T08:24:48Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00347-020-01191-6"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81427"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","Dringlichkeit der operativen Versorgung bei der rissbedingten Netzhautablösung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","258"],["dc.bibliographiccitation.journal","American Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","267"],["dc.bibliographiccitation.volume","169"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Weiss, Claudia"],["dc.contributor.author","Paulus, Eva-Maria"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Puri, Pankaj"],["dc.contributor.author","Berk, Husnu"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Wiedemann, Peter"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.date.accessioned","2018-11-07T10:09:02Z"],["dc.date.available","2018-11-07T10:09:02Z"],["dc.date.issued","2016"],["dc.description.abstract","PURPOSE: To compare the efficacy and safety of the European labels of ranibizumab 0.5 mg vs dexamethasone 0.7 mg in patients with macular edema secondary to central retinal vein occlusion (CRVO). DESIGN: Phase IIIb, multicenter, double-masked, randomized clinical trial. METHODS: Patients were randomized (1:1) to receive either monthly ranibizumab followed by pro re nata (PRN) treatment (n = 124) or 1 sustained-release dexamethasone implant followed by PRN sham injections (n = 119). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean change in BCVA, and adverse events (AEs). RESULTS: Of 243 patients, 185 (76.1%) completed the study. No difference was observed in BCVA between ranibizumab and dexamethasone at months 1 and 2. From month 3 to month 6, there was significant difference in BCVA gains in favor of ranibizumab. At month 6, mean average BCVA gain was significantly higher with ranibizumab than with dexamethasone (12.86 vs 2.96 letters; difference 9.91 letters, 95% confidence interval [6.51-43.30]; P < .0001). Mean injection number of ranibizumab was 4.52. Ocular AEs were reported in more patients in the dexamethasone than in the ranibizumab group (86.6% vs 55.6%). CONCLUSIONS: Using the European labels, similar efficacy was observed for ranibizumab and dexamethasone at months 1 and 2. However, ranibizumab maintained its efficacy throughout the study, whereas dexamethasone declined from month 3 onward. The main limitation of the study was that dexamethasone patients received only a single treatment during the 6-month study. In clinical practice, dexamethasone retreatment may be required earlier than 6 months. Safety findings were similar to those previously reported. (C) 2016 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","NOVARTIS PHARMA GMBH, GERMANY"],["dc.identifier.doi","10.1016/j.ajo.2016.04.020"],["dc.identifier.isi","000383637300027"],["dc.identifier.pmid","27163237"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39587"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-1891"],["dc.relation.issn","0002-9394"],["dc.title","Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Ophthalmologe"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Heinz, Peter"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Kohnen, Thomas"],["dc.contributor.author","Priglinger, Siegfried"],["dc.contributor.author","Bachmann, Werner"],["dc.contributor.author","Rieks, Johannes"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Reinhard, Thomas"],["dc.date.accessioned","2021-07-05T15:00:52Z"],["dc.date.available","2021-07-05T15:00:52Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00347-021-01411-7"],["dc.identifier.pii","1411"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87924"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.relation.eissn","1433-0423"],["dc.relation.issn","0941-293X"],["dc.title","Impact of the SARS-CoV-2 pandemic on ophthalmic care in Germany"],["dc.title.translated","Auswirkungen der SARS-CoV-2-Pandemie auf die ophthalmologische Versorgung in Deutschland"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e10"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","e18"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Berk, Hüsnü"],["dc.contributor.author","Eter, Nicole"],["dc.contributor.author","Lang, Gabriele E."],["dc.contributor.author","Rehak, Matus"],["dc.contributor.author","Taylor, Simon R."],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Weiss, Claudia"],["dc.contributor.author","Paulus, Eva-Maria"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2020-12-10T18:26:52Z"],["dc.date.available","2020-12-10T18:26:52Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/aos.13381"],["dc.identifier.issn","1755-375X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76196"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]